Tuesday, March 26, 2024

Correlate Energy Corp. (CIPI) Targets the U.S. Zero Operating Emissions Market

 

  • Correlate Energy, a publicly traded distributed energy solutions company, has positioned itself as the go-to company given the federal government’s push for greener buildings
  • The government’s proposed definition of zero operating emissions buildings, seeks consistency with a framework for long-term goal-setting
  • Correlate understands these changing tides and, through its three-pronged strategy, offers building owners and management the most technologically efficient and cost-effective ways to go green

Correlate Energy (OTCQB: CIPI), a publicly traded company positioned to capitalize on America’s move toward efficient energy sourcing and use, is aware of the growing pressure for buildings to become more energy efficient. This follows the federal government’s aggressive push for greener structures and its proposed definition geared toward increasing standardization, consistency, transparency, and accountability.

According to federal definitions, a zero operating emissions building is “Highly energy efficient, free of on-site emissions from energy use, and powered solely by clean energy sources.” The objective of this definition is to achieve consistency and lay down a framework for long-term goal setting. It leverages a building’s energy use as a foundation, offering incentives for existing building owners to improve their overall energy efficiency while providing a roadmap for new buildings to achieve energy efficiency upon construction (https://nnw.fm/DSoYD).

Correlate already recognizes that the energy grid in the U.S. is insufficient for the booming clean energy trend. In addition, it acknowledges that the current infrastructure poses a limit to green energy distribution. Still, it remains committed to helping buildings achieve net zero operating emissions, mainly by constructing the needed infrastructure to address this demand imbalance, while offering four main benefits with its offering. These include real cost savings, project investment funding, consistent long-term incentives, and robust customer demand.

Through its strategy of selling, retaining, and acquiring, Correlate has managed to carve out a significant market share. It is positioning itself as the all-in-one brand for total clean energy solutions, especially as the conversation around zero emissions buildings continues to proliferate and more stringent regulations are enforced.

This market positioning has seen various companies in the U.S. procure its products and services. Recently the company commissioned one of Illinois’ latest rooftop solar facilities for Continental Envelope’s manufacturing plant. This project is set to supply approximately 20-25% of the facility’s overall energy requirements (https://nnw.fm/mKsB5). It has now also completed a solar project at American Tire Distributors headquarters in Huntersville, North Carolina. This project is expected to economically reduce CO2 emissions by 5,463 tons over the next two decades, helping the company reduce its carbon footprint (https://nnw.fm/BABaO). 

As the federal government continues its push for net zero emissions buildings, Correlate anticipates a growth in the demand for its products and services. In 2023, over $1.7 trillion was estimated to be invested in technologies such as solar and wind power, electric vehicles, and batteries, making it the most ever spent on clean energy in a single year. It is projected that 2024 might surpass that figure, and Correlate is positioning itself to ride the wave. With its tried and tested solutions, the company has already asserted itself as the go-to brand for decentralized energy generation.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://nnw.fm/CIPI

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

SenesTech Inc. (NASDAQ: SNES) Closes Multiple Global Distribution Deals; Eyes 2024 as its Best Year Yet

 

  • SenesTech, a rapidly growing company specializing in highly effective fertility control solutions for animal pests, recently announced multiple product distribution deals outside the U.S.
  • In Europe, it entered into an agreement with Q-chem, a pest control product supplier in The Netherlands
  • In Australia, SenesTech entered into an agreement with Evicom, an environmental management firm with distribution in the country, as well as in New Zealand and the surrounding region
  • In Asia, the company partnered with Agro Technic PTE Ltd, a pest control product manufacturer and distributor headquartered in Singapore

SenesTech (NASDAQ: SNES), a rodent fertility control solutions provider, and the inventor of the only EPA-registered contraceptive for male and female rats, is pleased to announce multiple distribution deals globally in what marks a huge milestone for the company, just two months into the new year. These deals bring YTD 2024 total revenue up more than 80% compared to YTD 2023 (https://nnw.fm/pMDJA).

SenesTech also announced its foray into the European market with its distribution agreement with Q-chem, a pest control product supplier in the Netherlands. The move looks to tap into the growing demand for pest control products and services since the country first implemented an Integrated Pest Control (“IPM”) program four years ago with the explicit goal of reducing the reliance on anti-coagulant rodenticides. With its Evolve product, SenesTech is confident that it will dominate this market and become a leader in controlling rats with fertility control.

“Q-chem is a perfect partner for SenesTech as we begin our expansion into Europe, and Evolve(TM) fits into their portfolio perfectly,” noted Mr. Fruendt (https://nnw.fm/sVK36). 

SenesTech is following the country’s requisite regulatory procedure with Q-chem’s help. The process is expected to progress quickly, after which the product will be introduced in Europe.

New Zealand and Australia have also been prime potential markets for SenesTech. Its distribution agreement with Evicom, an environmental management firm based in Australia with distribution throughout Australia, New Zealand, and the surrounding region, opens the company to these two lucrative markets.

“Evicom is thrilled to be appointed exclusive distributors of Evolve for Australia and New Zealand,” noted Simon de Bono, Evicom’s Managing Director.

“Knowing SenesTech really cares about humanely managing animal populations through innovative fertility control aligns with our business strategy,” he added (https://nnw.fm/Svz57).

SenesTech also announced a distribution agreement with Agro Technic PTE Ltd, a Singapore pest control product manufacturer and distributor. This agreement will cover both a substantial initial stocking order and annual minimums. It will open SenesTech up to Singapore and surrounding regions, expanding its market reach and the potential number of customers it could acquire.

“Agro Technic has been at the forefront of bringing in innovative solutions for the public health sector since the 1970s. We continue to do so year on year, bringing to market solutions that are not only environmentally friendly but, most importantly, effective!” noted Heng Yiwei, Agro Technic’s Managing Director.

“The product range that SenesTech offers, is a perfect fit to our business model, long-term strategy, and market positioning and runs in tandem with the requirements of our garden city,” he added (https://nnw.fm/jdqNb).

SenesTech’s management is optimistic that these distribution agreements, coupled with its superior, tried and tested Evolve product, will set the company up for even more success this year, even as it continues to explore new growth opportunities.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://nnw.fm/SNES

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

3rd BioPharma Supply Chain & Logistics Nexus Conference to Address Supply Chain and Logistics Issues in Biopharmaceutical Industry

 Directors, managers, VPs, regulatory affairs personnel, and service providers of the logistics and operations verticals for the biopharma supply chain across Europe and North America are invited to attend the 3rd BioPharma Supply Chain & Logistics Nexus Conference being held April 25-26, 2024, at the Basel Mariott Hotel, Switzerland. The event aims to address critical issues and challenges in the supply chain and logistics within the biopharmaceutical industry.

The event is hosted by BioPharma Nexus, a premier company organizing prestigious conferences aiming to foster networking and business ties between pharmaceutical and biotech companies and their service providers. The focus lies in building robust relations such that the best healthcare services are available to patients worldwide. Service providers, managers, and company heads can identify and connect with partners to foster important scientific and healthcare collaborations.

Benefits of attending the conference:

  • Establishing networking and business relations among powerful industry leaders.
  • Gain insightful knowledge and learn about the latest trends in the biopharma spectrum.
  • Connect with the industry leaders to stay updated with the latest technological advancements as well as the target audience.
  • Learn the latest offerings and get innovative ideas and solutions for business operations.
  • Showcase your product and business solutions on a unified conference platform.

The 3rd BioPharma Nexus Conference brings together global leaders and experts on the biopharma supply chain to provide invaluable insights. They will explore topics ranging from improving the supply chain transparency and sustainability in temperature-controlled logistics to novel technologies and trends in the pharmaceutical supply chain. Special attention will be given to the issues and opportunities faced by Contract Manufacturing Organizations (CMOs/CDMOs). New entities can leverage the nexus forum to gain visibility and network with key industry stalwarts.

To know more, please visit https://nnw.fm/kCTYC

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

 

  • CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors
  • Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally
  • The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval
  • The company recently completed the enrollment of patients in its potentially pivotal global clinical trial
  • Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost these efforts, the company has enlisted an experienced, growing team. Recently, CNS Pharmaceuticals appointed Amy Mahery to its Board of Directors (https://nnw.fm/h05vo).

A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas. She has held diverse commercial leadership roles in the U.S. and globally, spanning sales, marketing, and market access where she has been part of teams that commercialized and launched drugs in various therapeutic areas, from oncology and neurology to immunology.

In her current role as the Chief Commercial Officer of Roivant Sciences (NASDAQ: ROIV), a publicly traded biopharmaceutical company with a $9 billion market cap, Ms. Mahery is playing a vital role in facilitating Roivant’s transformation from a clinical development-focused company to an end-to-end biotech leader. She has worked to establish the company’s commercial operations and capabilities, efforts that have seen Roivant achieve profitable growth across its entire portfolio of over 10 affiliate companies called Vants. Ms. Mahery provides direct commercial leadership to the Vants during the start-up phase. Prior to taking up this role, she held multiple leadership roles at EMD Serono, Inc., a healthcare subsidiary of Merck KGaA.

“We are incredibly pleased to welcome Amy to the Board. She is a proven commercial leader with a wealth of knowledge and expertise amassed over the course of her 20+ years in the industry. As the company continues to advance Berubicin toward completion of its global potentially pivotal clinical trial and potential regulatory approval, her guidance, insight, and vast pharma industry network will truly be invaluable,” conveyed Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors. “We remain committed to serving GBM patients in desperate need of a treatment, and look forward to leveraging Amy’s extensive experience and commercial leadership to assist in positioning the company for success.”

A strong supporter of innovation that brings value to patients, organizations, and society, Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (“GBM”) treatment, saying, “I have been intrigued by the company’s pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team.”

Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response.

CNS Pharmaceuticals is currently undertaking a potentially pivotal study of Berubicin for the treatment of GBM. The company completed in January the planned enrollment of 247 participants across 46 clinical trial sites in the U.S., Italy, France, Spain, and Switzerland (https://nnw.fm/crWbS). The company remains hopeful in its efforts to address GBM and intends to take advantage of the extensive expertise of Ms. Mahery and other members of its capable team to drive success.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN